<DOC>
	<DOCNO>NCT01918852</DOCNO>
	<brief_summary>The study two-arm randomise phase III trial . Patients randomise receive capecitabine ( arm A ) S-1 ( arm B ) . Bevacizumab may add accord choice investigator . Patients follow 3-weekly outpatient clinic , toxicity assess accord study protocol guideline . Patients evaluate every 3 cycle response . Upon disease progression patient treat accord local investigator</brief_summary>
	<brief_title>S-1 Versus Capecitabine First Line Treatment MCC Patients .</brief_title>
	<detailed_description>Capecitabine , oral fluoropyrimidine , show comparable efficacy well tolerability compare bolus 5-FU/LV . However , capecitabine high incidence hand-foot syndrome ( HFS ) . HFS characterize erythema , dysesthesia and/or paresthesia palm hand soles foot . In advanced stage , desquamation , ulceration blister occur . Although HFS life threatening , cause significant discomfort impairment function , especially elderly patient . This adverse event become particularly relevant since many patient may require administration capecitabine prolong period time . S-1 ( Teysuno® ) oral fluoropyrimidine show comparable efficacy 5FU capecitabine gastrointestinal cancer associate much low incidence HFS . Studies S-1 mainly perform Asian patient , population know difference tumour biology toxicity compare Western population . S-1 show comparable efficacy fluoropyrimidines monotherapy combination chemotherapy schedule several gastrointestinal tumor . However , give lack data prospective study S-1 monochemotherapy metastatic colorectal cancer Western patient , study design compare S-1 capecitabine monotherapy term safety , particular interest HFS , metastatic colorectal cancer patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histological proof colorectal cancer . Distant metastasis ( patient local recurrence eligible ) . Unidimensionally measurable disease ( ≥1 cm spiral CT scan ≥2 cm chest Xray ; liver ultrasound allow ) . Serum CEA may use parameter disease evaluation . In case previous radiotherapy , least one measurable lesion locate outside irradiated field . Age ≥ 18 year Planned treatment fluoropyrimidine monotherapy without bevacizumab . WHO performance status 02 ( Karnofsky PS ≥70 % ) Adequate bone marrow function ( Hb ≥ 6.0 mmol/L , absolute neutrophil count ≥1.5 x 109/L , platelet ≥ 100 x 109/L ) , renal function ( serum creatinine ≤ 1.5x ULN creatinine clearance , Cockroft formula , ≥30 ml/min ) , liver function ( serum bilirubin ≤ 2 x ULN , serum transaminase ≤ 3 x ULN without presence liver metastases ≤ 5x ULN presence liver metastasis ) . Life expectancy &gt; 12 week . Negative pregnancy test woman childbearing potential . Expected adequacy followup . Institutional Review Board approval . Written informed consent . Prior adjuvant treatment stage II/III colorectal cancer complete within 6 month prior randomisation . Any prior adjuvant treatment resection distant metastasis . Any previous systemic treatment metastatic disease . History clinical signs/symptoms CNS metastasis . History second malignancy &lt; 5 year exception adequately treat carcinoma cervix basal/squamous cell carcinoma skin . Previous intolerance capecitabine . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency treatment within 4 week DPD inhibitor , include sorivudine chemically related analogue brivudine . Planned radical resection metastasis downsize systemic treatment . Significant cardiovascular disease &lt; 1 yr randomisation ( symptomatic congestive heart failure , myocardial ischemia infarction , unstable angina pectoris , serious uncontrolled cardiac arrhythmia , arterial thrombosis , cerebrovascular event , pulmonary embolism ) . Any significant cardiovascular event previous fluoropyrimidine therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hand-foot syndrome</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Fluoropyrimidine</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Teysuno</keyword>
	<keyword>S1</keyword>
</DOC>